




BACKGROUND NOTE Each year WHO and UNICEF jointly review reports submitted by Member States regarding national immunization coverage, finalized survey reports as well as data from published and grey literature. Based on these data, with due consideration to potential biases and the views of local experts, WHO and UNICEF attempt to distinguish between situations where available empirical data accurately reflect immunization system performance and those where the data are likely compromised and present a misleading view of coverage. The estimates refer to immunizations delivered through routine immunization services to children less than 12 months of age, or at the age specified in the recommended immunization schedule, for whom vaccinations are recorded. Immunizations received through supplemental immunization activities, such as polio and measles campaigns, are not included.

WHO and UNICEF estimates are country-specific; that is to say, each country's data are reviewed individually, and data are not borrowed from other countries in the absence of data. Estimates are not based on ad hoc adjustments to reported data; in some instances empirical data are available from a single source, usually the nationally reported coverage data. In cases where no data are available for a given country/vaccine/year combination, data are considered from earlier and later years and interpolated to estimate coverage for the missing year(s). In cases where data sources are mixed and show large variation, an attempt is made to identify the most likely estimate with consideration of the possible biases in available data. For methods see:

* Burton et al. 2009. Bull World Health Organ. * Burton et al. 2012. PLoS One.
* Brown et al. 2013. Open Pub Health Journal. * Danovaro-Holliday et al. 2021. Gates Open Res.

DATA SOURCES

ADMINISTRATIVE coverage: Reported by national authorities and based on aggregated administrative reports from health service providers on the number of vaccinations administered during a given period (numerator data) and reported target population data (denominator data). May be biased by inaccurate numerator and/or denominator data.

OFFICIAL coverage: Estimated coverage reported by national authorities that reflects their assessment of the most likely coverage based on any combination of administrative coverage, survey-based estimates or other data sources or adjustments. Approaches to determine OFFICIAL coverage may differ across countries.

SURVEY coverage: Based on estimated coverage from population-based household surveys among children aged 6-11, 12-23 or 24-35 months following a review of survey methods and results. Information is based on the combination of vaccination history from documented evidence or caregiver recall. Survey results are considered for the appropriate birth cohort based on data collection period.

ABBREVIATIONS AND DEFINITIONS

BCG: percentage of births who received one dose of Bacillus Calmette Guerin vaccine.

DTP1 / DTP3: percentage of surviving infants who received the 1st / 3rd dose, respectively, of diphtheria and tetanus toxoid with pertussis containing vaccine.

IPV1: percentage of surviving infants who received the first dose of inactivated polio vaccine.

IPVC: percentage of surviving infants who received the final recommended dose of IPV in the primary series, according to the national immunization schedule primary series (e.g., second or third dose).

MCV1: percentage of surviving infants who received the 1st dose of measles containing vaccine. In countries where the national schedule recommends the 1st dose of MCV at 12 months or later based on the epidemiology of disease in the country, coverage estimates reflect the percentage of children who received the 1st dose of MCV as recommended.

MCV2: percentage of children who received the 2nd dose of measles containing vaccine according to the nationally recommended schedule.

RCV1: percentage of surviving infants who received the 1st dose of rubella containing vaccine. Coverage estimates are based on WHO and UNICEF estimates of coverage for the dose of measles containing vaccine that corresponds to the first measles-rubella combination vaccine. Nationally reported coverage of RCV is not taken into consideration in the production of the estimate.

HEPB: percentage of births which received a dose of hepatitis B vaccine within 24 hours of delivery. Estimates of hepatitis B birth dose coverage are produced only for countries with a universal birth dose policy. Estimates are not produced for countries that recommend a birth dose to infants born to HEPB virus-infected mothers only or where there is insufficient information to determine whether vaccination is within 24 hours of birth.

HEPB3: percentage of surviving infants who received the 3rd dose of hepatitis B containing vaccine following the birth dose.

HIB3: percentage of surviving infants who received the 3rd dose of Haemophilus influenzae type b containing vaccine.

ROTAC: percentage of surviving infants who received the final recommended dose of rotavirus vaccine, which can be either the 2nd or the 3rd dose depending on the vaccine.

PCVC: percentage of surviving infants who received the final recommended dose of pneumococcal conjugate vaccine according to the national immunization schedule (e.g., second or third dose).


YFV: percentage of surviving infants who received one dose of yellow fever vaccine in countries where YFV is part of the national immunization schedule for children or is recommended in at risk areas; coverage estimates are annualized for the entire cohort of surviving infants.

MENGA: percentage of children who received one dose of meningococcal A conjugate vaccine. MENGA coverage estimates produced for countries in the meningitis belt of sub-Saharan Africa.

Disclaimer: All reasonable precautions have been taken by the World Health Organization and United Nations Children's Fund to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization or United Nations Children's Fund be liable for damages arising from its use.

Bangladesh - BCG

BGD - BCG



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	99	99	99	99	99	99	99	99	99	99	99	94
Estimate GoC	●	●	●	●	●	●	●	●	●	●	●	●
Official	99	99	99	99	99	100	100	100	-	100	99	99
Administrative	105	117	114	115	114	115	110	117	118	126	121	95
Survey	99	*	98	100	100	-	-	99	99	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:


- 2025: Estimate is based on the relationship between reported number of doses in 2024 and 2025, applied to the 2024 estimated coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Estimate informed by extrapolation from reported data. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2023: Estimate informed by extrapolation from reported data. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2022: Estimate based on extrapolation from data reported by national government supported by survey.Survey evidence of 99 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered.Reported data excluded because 118 percent greater than 100 percent. Reported data excluded due to an increase from 100 percent to 118 percent with decrease to 100 percent. Estimate challenged by: D-
- 2021: Estimate based on extrapolation from data reported by national government supported by survey.Survey evidence of 99 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2020: Estimate informed by extrapolation from reported data. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-
- 2019: Estimate informed by extrapolation from reported data. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2018: Estimate based on extrapolation from data reported by national government supported by survey.Survey evidence of 100 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2017: Estimate based on extrapolation from data reported by national government supported by survey.Survey evidence of 100 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2016: Estimate based on extrapolation from data reported by national government supported by survey.Survey evidence of 98 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-

Bangladesh - BCG

- 2015: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 100 percent based on 2 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Programme reports one month national level stockout. Estimate challenged by: D-
- 2014: Estimate of 99 percent assigned by working group. Estimate informed by survey result. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Target population revised downward based on 2011 census results. Estimate challenged by: D-R-

Bangladesh - DTP1

BGD - DTP1



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	99	99	99	99	99	99	99	99	99	99	99	93
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	93	93	94	98	98	100	100	100	-	100	99	99
Administrative	110	121	119	118	117	120	113	121	122	125	120	90
Survey	99	*	99	100	100	-	-	99	99	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2025: Estimate is based on the relationship between reported number of doses in 2024 and 2025, applied to the 2024 estimated coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2023: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Programme reports a vaccine stockout at the subnational level. Estimate challenged by: D-R-
- 2022: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 99 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported data excluded because 122 percent greater than 100 percent. Reported data excluded due to an increase from 100 percent to 122 percent with decrease to 100 percent. Estimate challenged by: D-R-
- 2021: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 99 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2018 and 2021 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2018 and 2021 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2018: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 100 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2017: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 100 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2016: Estimate informed by estimated DTP3 coverage adjusted for dropout. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2015: Survey evidence does not support reported data. Estimate based on survey result. Survey


Bangladesh - DTP1

evidence of 99 percent based on 2 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-

2014: Estimate of 99 percent assigned by working group. Estimate informed by survey result. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Target population revised downward based on 2011 census results. Estimate challenged by: D-R-

Bangladesh - DTP3

BGD - DTP3



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	97	98	98	98	98	98	97	97	97	97	97	92
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	93	93	94	90	90	93	93	93	-	93	92	92
Administrative	109	120	118	116	114	118	110	118	120	120	114	87
Survey	97	*	96	99	99	-	-	98	98	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:


- 2025: Estimate is based on the relationship between reported number of doses in 2024 and 2025, applied to the 2024 estimated coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2023: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Programme reports a vaccine stockout at the subnational level. Estimate challenged by: D-R-
- 2022: Estimate of 97 percent assigned by working group. Estimate based on survey coverage estimate adjusted for recall bias. Bangladesh EPI Coverage Evaluation Survey 2023 record or recall results of 98 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 58 percent and 3rd dose record only coverage of 57 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported data excluded because 120 percent greater than 100 percent. Reported data excluded due to an increase from 93 percent to 120 percent with decrease to 93 percent. Estimate challenged by: D-R-
- 2021: Estimate of 97 percent assigned by working group. Estimate based on survey coverage estimate adjusted for recall bias. Bangladesh EPI Coverage Evaluation Survey 2023 record or recall results of 98 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 54 percent and 3rd dose record only coverage of 53 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2018 and 2021 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2018 and 2021 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2018: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 99 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2017: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 99 percent based on 1 survey(s). Reported data excluded.

Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-

- 2016: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 98 percent based on 1 survey(s). Bangladesh Demographic and Health Survey 2017-2018 record or recall results of 96 percent modified for recall bias to 98 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 74 percent and 3rd dose record only coverage of 73 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2015: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 98 percent based on 2 survey(s). Bangladesh Demographic and Health Survey 2017-2018 record or recall results of 96 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 98 percent, 1st dose record only coverage of 67 percent and 3rd dose record only coverage of 66 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2014: Estimate of 97 percent assigned by working group. Estimate informed by survey result. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Target population revised downward based on 2011 census results. Estimate challenged by: D-R-

Bangladesh - HEPB3

BGD - HEPB3



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	97	98	98	98	98	98	98	97	97	97	97	92
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	93	93	94	90	90	93	93	93	-	93	92	92
Administrative	109	120	118	116	114	118	110	118	120	120	114	87
Survey	97	*	96	99	99	-	-	98	98	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.


Description:

- 2025: Estimate based on estimated DTP3 coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: R-
- 2023: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Programme reports a vaccine stockout at the subnational level. Estimate challenged by: D-R-
- 2022: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 97 percent based on 1 survey(s). Bangladesh EPI Coverage Evaluation Survey 2023 record or recall results of 98 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 58 percent and 3rd dose record only coverage of 57 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported data excluded because 120 percent greater than 100 percent. Reported data excluded due to an increase from 93 percent to 120 percent with decrease to 93 percent. Estimate challenged by: D-R-
- 2021: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 97 percent based on 1 survey(s). Bangladesh EPI Coverage Evaluation Survey 2023 record or recall results of 98 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 54 percent and 3rd dose record only coverage of 53 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2020: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-R-
- 2019: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2018: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2017: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-

- 2016: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Bangladesh Demographic and Health Survey 2017-2018 record or recall results of 96 percent modified for recall bias to 98 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 74 percent and 3rd dose record only coverage of 73 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2015: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 98 percent based on 2 survey(s). Bangladesh Demographic and Health Survey 2017-2018 record or recall results of 96 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 98 percent, 1st dose record only coverage of 67 percent and 3rd dose record only coverage of 66 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2014: Estimate of 97 percent assigned by working group. Estimate informed by survey result. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Target population revised downward based on 2011 census results. Estimate challenged by: D-R-

Bangladesh - HIB3

BGD - HIB3



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	97	98	98	98	98	98	98	97	97	97	97	92
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	93	93	94	90	90	93	93	93	-	93	92	92
Administrative	109	120	118	116	114	118	110	118	120	120	114	87
Survey	97	*	96	99	99	-	-	98	98	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:


- 2025: Estimate based on estimated DTP3 coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: R-
- 2023: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Programme reports a vaccine stockout at the subnational level. Estimate challenged by: D-R-
- 2022: Estimate of 97 percent assigned by working group. Estimate based on survey coverage estimate adjusted for recall bias. Bangladesh EPI Coverage Evaluation Survey 2023 record or recall results of 98 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 58 percent and 3rd dose record only coverage of 57 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported data excluded because 120 percent greater than 100 percent. Reported data excluded due to an increase from 93 percent to 120 percent with decrease to 93 percent. Estimate challenged by: D-R-
- 2021: Estimate of 97 percent assigned by working group. Estimate based on survey coverage estimate adjusted for recall bias. Bangladesh EPI Coverage Evaluation Survey 2023 record or recall results of 98 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 54 percent and 3rd dose record only coverage of 53 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2020: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-R-
- 2019: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2018: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2017: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-

Bangladesh - HIB3

- 2016: Estimate of 98 percent assigned by working group. Estimate based on estimated DTP3. Bangladesh Demographic and Health Survey 2017-2018 record or recall results of 96 percent modified for recall bias to 98 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 74 percent and 3rd dose record only coverage of 73 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2015: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 98 percent based on 2 survey(s). Bangladesh Demographic and Health Survey 2017-2018 record or recall results of 96 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 98 percent, 1st dose record only coverage of 67 percent and 3rd dose record only coverage of 66 percent. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2014: Estimate of 97 percent assigned by working group. Estimate informed by survey result. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Target population revised downward based on 2011 census results. Estimate challenged by: D-R-

Bangladesh - PCVC

BGD - PCVC



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	-	48	97	99	98	99	99	97	97	97	97	94
Estimate GoC	-	●	●	●	●	●	●	●	●	●	●	●
Official	-	48	-	-	-	93	93	93	-	93	92	-
Administrative	-	48	113	120	115	118	110	118	120	114	106	89
Survey	-	92	92	99	98	-	-	98	98	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:


- 2025: Estimate is based on the relationship between reported number of administered doses for DTP3 and PCVC applied to the DTP3 estimated coverage. Reported data excluded. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Reported data calibrated to 2022 levels. Reported data excluded. Estimate challenged by: R-
- 2023: Reported data calibrated to 2022 levels. Programme reports one-month vaccine stockout at the national level. Estimate challenged by: D-R-
- 2022: Estimate of 97 percent assigned by working group. Estimate based on survey coverage estimate adjusted for recall bias. Bangladesh EPI Coverage Evaluation Survey 2023 record or recall results of 98 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 58 percent and 3rd dose record only coverage of 57 percent. Reported data excluded because 120 percent greater than 100 percent. Reported data excluded due to an increase from 93 percent to 120 percent with decrease to 93 percent. Estimate challenged by: D-R-
- 2021: Estimate of 97 percent assigned by working group. Estimate based on survey coverage estimate adjusted for recall bias. Bangladesh EPI Coverage Evaluation Survey 2023 record or recall results of 98 percent modified for recall bias to 97 percent based on 1st dose record or recall coverage of 99 percent, 1st dose record only coverage of 54 percent and 3rd dose record only coverage of 53 percent. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2018 and 2021 levels. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: R-
- 2019: Reported data calibrated to 2018 and 2021 levels. Estimate challenged by: D-R-
- 2018: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 98 percent based on 1 survey(s). Reported data excluded because 115 percent greater than 100 percent. Estimate challenged by: D-R-
- 2017: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 99 percent based on 1 survey(s). Reported data excluded because 120 percent greater than 100 percent. Estimate challenged by: D-R-
- 2016: Estimate of 97 percent assigned by working group. Estimate informed by survey result for DTP3 coverage. Bangladesh Demographic and Health Survey 2017-2018 record or recall results of 92 percent modified for recall bias to 94 percent based on 1st dose record or recall coverage of 98 percent, 1st dose record only coverage of 74 percent and 3rd dose record only coverage of 71 percent. Reported data excluded because 113 percent greater than 100 percent. Estimate challenged by: D-R-
- 2015: Estimate informed by reported data. Bangladesh Demographic and Health Survey 2017-2018 results ignored by working group. Survey cohort coincides with vaccine introduction. Bangladesh Demographic and Health Survey 2017-2018 record or recall results of 92 percent modified for recall bias to 93 percent based on 1st dose record or recall coverage of

Bangladesh - PCVC

96 percent, 1st dose record only coverage of 66 percent and 3rd dose record only coverage of 64 percent. Pneumococcal conjugate vaccine introduced in March 2015. Estimate challenged by: R-S-

Bangladesh - IPV1

BGD - IPV1



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	-	51	37	37	75	92	96	99	99	99	99	95
Estimate GoC	-	●	●	●	●	●	●	●	●	●	●	●
Official	-	73	-	-	-	48	48	48	-	48	94	94
Administrative	-	73	33	39	91	111	108	118	119	120	115	89
Survey	-	65	37	-	76	-	-	98	98	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2025: Estimate is based on the relationship between reported number of doses in 2024 and 2025, applied to the 2024 estimated coverage. Reported data excluded. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Reported data calibrated to 2022 levels. Estimate challenged by: D-R-S-
- 2023: Reported data calibrated to 2022 levels. Reported data excluded due to decline in reported coverage from 119 percent to 48 percent with increase to 94 percent. Estimate challenged by: R-S-
- 2022: Estimate of 99 percent assigned by working group. Estimate based on survey coverage. Reported data excluded because 119 percent greater than 100 percent. Reported data excluded due to an increase from 48 percent to 119 percent with decrease to 48 percent. Estimate challenged by: D-R-
- 2021: Estimate of 99 percent assigned by working group. Estimate based on survey coverage. Estimate challenged by: D-R-
- 2020: Official reported coverage is last survey estimate before full IPV roll out. Estimate informed by the relative relationship between estimated and reported administrative coverage for DTP3 applied to reported administrative coverage for IPV second fractional dose. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-R-S-
- 2019: Estimate informed by the relative relationship between estimated and reported administrative coverage for DTP3 applied to reported administrative coverage for IPV1. Estimate challenged by: D-R-S-
- 2018: Estimate informed by the difference between reported administrative coverage and estimated coverage for DTP3. IPV is administered as a fractional dose since December 2017. Reported data excluded due to an increase from 39 percent to 91 percent with decrease to 48 percent. Programme reports use of fractional IPV dose. Reported data reflect second fractional dose. Estimate challenged by: D-R-S-
- 2017: Estimate of 37 percent assigned by working group. Estimate informed by survey results. Estimate challenged by: R-S-
- 2016: Estimate of 37 percent assigned by working group. Estimate informed by survey results. Estimate informed by reported data. Programme reports vaccine stockout of unspecified duration. Estimate challenged by: R-S-
- 2015: Estimate of 51 percent assigned by working group. Inactivated polio vaccine introduced mid-year 2015. Programme reports 1.5 month stockout. Estimate informed by difference between reported admin coverage and estimate for DTP3 administered at 14 weeks. GoC=Assigned by working group. GoC assigned to maintain consistency across vaccines.

Bangladesh - MCV1

BGD - MCV1



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	94	97	97	97	97	97	97	97	96	96	96	90
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	90	90	92	92	92	93	93	93	-	89	86	86
Administrative	109	120	118	116	115	117	108	118	120	125	124	93
Survey	94	*	91	97	96	-	-	97	96	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:


- 2025: Estimate is based on the relationship between reported number of doses in 2024 and 2025, applied to the 2024 estimated coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2023: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2022: Estimate of 96 percent assigned by working group. Estimate based on survey coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported data excluded because 120 percent greater than 100 percent. Reported data excluded due to an increase from 93 percent to 120 percent with decrease to 89 percent. Estimate challenged by: D-R-
- 2021: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 97 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2020: Estimate informed by extrapolation from reported data. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-
- 2019: Estimate informed by extrapolation from reported data. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2018: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 96 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2017: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 97 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2016: Estimate based on extrapolation from data reported by national government supported by survey. Survey evidence of 91 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-
- 2015: Estimate based on extrapolation from data reported by national government supported

Bangladesh - MCV1

by survey. Survey evidence of 94 percent based on 2 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-

2014: Estimate of 94 percent assigned by working group. Estimate informed by survey result. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Target population revised downward based on 2011 census results. Estimate challenged by: D-R-

Bangladesh - RCV1



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	94	97	97	97	97	97	97	97	96	96	96	90
Estimate GoC	●	●	●	●	●	●	●	●	●	●	●	●
Official	90	90	92	92	92	93	93	93	-	89	86	86
Administrative	109	120	118	116	-	117	108	118	120	125	124	93
Survey	94	*	91	97	96	-	-	97	96	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.


In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2025: Estimate based on estimated MCV1 coverage. Reported data excluded. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Estimate based on estimated MCV1. Estimate challenged by: D-R-
- 2023: Estimate based on estimated MCV1. Estimate challenged by: D-R-
- 2022: Estimate based on estimated MCV1. Reported data excluded because 120 percent greater than 100 percent. Reported data excluded due to an increase from 93 percent to 120 percent with decrease to 89 percent. Estimate challenged by: D-R-
- 2021: Estimate based on estimated MCV1. Estimate challenged by: D-
- 2020: Estimate based on estimated MCV1. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-
- 2019: Estimate based on estimated MCV1. Estimate challenged by: D-
- 2018: Estimate based on estimated MCV1. Estimate challenged by: D-
- 2017: Estimate based on estimated MCV1. Estimate challenged by: D-
- 2016: Estimate based on estimated MCV1. Estimate challenged by: D-
- 2015: Estimate based on estimated MCV1. Estimate challenged by: D-
- 2014: Estimate based on estimated MCV1. Target population revised downward based on 2011 census results. Estimate challenged by: D-R-

Bangladesh - MCV2

BGD - MCV2



	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Estimate	89	90	92	93	93	93	93	93	93	93	93	86
Estimate GoC	•	•	•	•	•	•	•	•	•	•	•	•
Official	70	70	81	83	83	89	89	89	-	89	81	81
Administrative	104	115	115	114	113	115	107	115	116	123	121	91
Survey	-	86	83	-	93	-	-	-	93	-	-	-

The WHO and UNICEF estimates of national immunization coverage (wuenic) are based on data and information that are of varying, and, in some instances, unknown quality. Beginning with the 2011 revision we describe the grade of confidence (GoC) we have in these estimates. As there is no underlying probability model upon which the estimates are based, we are unable to present classical measures of uncertainty, e.g., confidence intervals. Moreover, we have chosen not to make subjective estimates of plausibility/certainty ranges around the coverage. The GoC reflects the degree of empirical support upon which the estimates are based. It is not a judgment of the quality of data reported by national authorities.

- Estimate is supported by reported data [R+], coverage recalculated with an independent denominator from the World Population Prospects: 2024 revision from the UN Population Division (D+), and at least one supporting survey within 2 years [S+]. While well supported, the estimate still carries a risk of being wrong.
- Estimate is supported by at least one data source; [R+], [S+], or [D+]; and no data source, [R-], [D-], or [S-], challenges the estimate.
- There are no directly supporting data; or data from at least one source; [R-], [D-], [S-]; challenge the estimate.

In all cases these estimates should be used with caution and should be assessed in light of the objective for which they are being used.

Description:

- 2025: Estimate is based on the relationship between reported number of doses in 2024 and 2025, applied to the 2024 estimated coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported target population increased of 21 to 25 percent between 2024 and 2025. Estimate challenged by: D-R-
- 2024: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2023: Reported data calibrated to 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2022: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 93 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Reported data excluded because 116 percent greater than 100 percent. Reported data excluded due to an increase from 89 percent to 116 percent with decrease to 89 percent. Estimate challenged by: D-R-
- 2021: Reported data calibrated to 2018 and 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2020: Reported data calibrated to 2018 and 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. While reported administrative coverage consistently appears overestimated when compared to recent survey results, declines in reported administered doses are neither reflected in the reported official coverage nor the estimated coverage. Estimate challenged by: D-R-
- 2019: Reported data calibrated to 2018 and 2022 levels. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2018: Survey evidence does not support reported data. Estimate based on survey result. Survey evidence of 93 percent based on 1 survey(s). Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2017: Estimate of 93 percent assigned by working group. Estimate based on estimated MCV1 coverage adjusted for the difference between reported administrative MCV1 and MCV2 coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2016: Estimate of 92 percent assigned by working group. Estimate based on estimated MCV1 coverage adjusted for the difference between reported administrative MCV1 and MCV2 coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-
- 2015: Estimate of 90 percent assigned by working group. Estimate based on estimated MCV1

Bangladesh - MCV2

coverage adjusted for the difference between reported administrative MCV1 and MCV2 coverage. Reported data excluded. Nationally reported data for official coverage includes only valid doses administered. Estimate challenged by: D-R-

2014: Estimate of 89 percent assigned by working group. Estimate based on estimated MCV1 coverage adjusted for the difference between reported administrative MCV1 and MCV2 coverage. Target population revised downward based on 2011 census results. Estimate challenged by: D-R-

Bangladesh - Survey Details

NOTE A survey to measure vaccination coverage for infants (i.e., children aged 0-11 months) will sample children aged 12-23 months at the time of survey to capture the youngest annual cohort of children who should have completed the vaccination schedule. Because WUENIC are for infant vaccinations, survey data in this report are presented to reflect the birth year of the youngest survey cohort. For example, results for a survey conducted during December 2020 among children aged 12-23 months at the time of the survey reflect the immunization experience of children born in 2019. Depending on the timing of survey field work, results may reflect the immunization experience of children born and vaccinated one or two years prior to the survey field work.

The survey results below present vaccination coverage estimates by antigen, confirmation method, and child's age at the time of the survey. Coverage based on **Recall** reflects information based upon a mother's or caregiver's memory. Coverage based on **Record** reflects information drawn from documented vaccination history in home- and/or facility-based records. **Evidence seen** reflects the percentage of children in the sample with documented evidence of vaccination history seen by the survey team.

2022 Bangladesh EPI Coverage Evaluation Survey 2023

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	40.9	12-23 m	48912	57
BCG	Record	57.9	12-23 m	48912	57
BCG	Record or Recall	98.8	12-23 m	48912	57
DTP1	Recall	40.9	12-23 m	48912	57
DTP1	Record	57.8	12-23 m	48912	57
DTP1	Record or Recall	98.8	12-23 m	48912	57
DTP3	Recall	40.5	12-23 m	48912	57
DTP3	Record	57.2	12-23 m	48912	57
DTP3	Record or Recall	97.7	12-23 m	48912	57
HEPB1	Recall	40.9	12-23 m	48912	57
HEPB1	Record	57.8	12-23 m	48912	57
HEPB1	Record or Recall	98.8	12-23 m	48912	57
HEPB3	Recall	40.5	12-23 m	48912	57
HEPB3	Record	57.2	12-23 m	48912	57
HEPB3	Record or Recall	97.7	12-23 m	48912	57
HIB1	Recall	40.9	12-23 m	48912	57
HIB1	Record	57.8	12-23 m	48912	57
HIB1	Record or Recall	98.8	12-23 m	48912	57
HIB3	Recall	40.5	12-23 m	48912	57

HIB3	Record	57.2	12-23 m	48912	57
HIB3	Record or Recall	97.7	12-23 m	48912	57
IPV1	Recall	40.8	12-23 m	48912	57
IPV1	Record	56.9	12-23 m	48912	57
IPV1	Record or Recall	97.7	12-23 m	48912	57
MCV1	Recall	40.2	12-23 m	48912	57
MCV1	Record	55.4	12-23 m	48912	57
MCV1	Record or Recall	95.5	12-23 m	48912	57
MCV2	Recall	43.7	24-35 m	49007	50
MCV2	Record	49.4	24-35 m	49007	50
MCV2	Record or Recall	93.1	24-35 m	49007	50
PCV1	Recall	40.9	12-23 m	48912	57
PCV1	Record	57.8	12-23 m	48912	57
PCV1	Record or Recall	98.8	12-23 m	48912	57
PCVC	Recall	40.5	12-23 m	48912	57
PCVC	Record	57.2	12-23 m	48912	57
PCVC	Record or Recall	97.7	12-23 m	48912	57
RCV1	Recall	40.2	12-23 m	48912	57
RCV1	Record	55.4	12-23 m	48912	57
RCV1	Record or Recall	95.5	12-23 m	48912	57

2021 Bangladesh EPI Coverage Evaluation Survey 2023

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	45.1	24-35 m	49007	50
BCG	Record	53.8	24-35 m	49007	50
BCG	Record or Recall	98.9	24-35 m	49007	50
DTP1	Recall	45	24-35 m	49007	50
DTP1	Record	53.8	24-35 m	49007	50
DTP1	Record or Recall	98.8	24-35 m	49007	50
DTP3	Recall	44.9	24-35 m	49007	50
DTP3	Record	53.1	24-35 m	49007	50
DTP3	Record or Recall	98	24-35 m	49007	50
HEPB1	Recall	45	24-35 m	49007	50
HEPB1	Record	53.8	24-35 m	49007	50
HEPB1	Record or Recall	98.8	24-35 m	49007	50
HEPB3	Recall	44.9	24-35 m	49007	50
HEPB3	Record	53.1	24-35 m	49007	50
HEPB3	Record or Recall	98	24-35 m	49007	50

Bangladesh - Survey Details

HIB1	Recall	45	24-35 m	49007	50
HIB1	Record	53.8	24-35 m	49007	50
HIB1	Record or Recall	98.8	24-35 m	49007	50
HIB3	Recall	44.9	24-35 m	49007	50
HIB3	Record	53.1	24-35 m	49007	50
HIB3	Record or Recall	98	24-35 m	49007	50
IPV1	Recall	45	24-35 m	49007	50
IPV1	Record	53	24-35 m	49007	50
IPV1	Record or Recall	98	24-35 m	49007	50
MCV1	Recall	44.5	24-35 m	49007	50
MCV1	Record	52	24-35 m	49007	50
MCV1	Record or Recall	96.5	24-35 m	49007	50
PCV1	Recall	45	24-35 m	49007	50
PCV1	Record	53.8	24-35 m	49007	50
PCV1	Record or Recall	98.8	24-35 m	49007	50
PCVC	Recall	44.7	24-35 m	49007	50
PCVC	Record	53.3	24-35 m	49007	50
PCVC	Record or Recall	98	24-35 m	49007	50
RCV1	Recall	44.5	24-35 m	49007	50
RCV1	Record	52	24-35 m	49007	50
RCV1	Record or Recall	96.5	24-35 m	49007	50

2018 Bangladesh EPI Coverage Evaluation Survey 2019

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	12.1	12-23 m	40247	87
BCG	Record	87.6	12-23 m	40247	87
BCG	Record or Recall	99.7	12-23 m	40247	87
DTP1	Recall	12.1	12-23 m	40247	87
DTP1	Record	87.6	12-23 m	40247	87
DTP1	Record or Recall	99.7	12-23 m	40247	87
DTP3	Recall	12.1	12-23 m	40247	87
DTP3	Record	86.6	12-23 m	40247	87
DTP3	Record or Recall	98.7	12-23 m	40247	87
HEPB1	Recall	12.1	12-23 m	40247	87
HEPB1	Record	87.6	12-23 m	40247	87
HEPB1	Record or Recall	99.7	12-23 m	40247	87
HEPB3	Recall	12.1	12-23 m	40247	87
HEPB3	Record	86.6	12-23 m	40247	87

HEPB3	Record or Recall	98.7	12-23 m	40247	87
HIB1	Recall	12.1	12-23 m	40247	87
HIB1	Record	87.6	12-23 m	40247	87
HIB1	Record or Recall	99.7	12-23 m	40247	87
HIB3	Recall	12.1	12-23 m	40247	87
HIB3	Record	86.6	12-23 m	40247	87
HIB3	Record or Recall	98.7	12-23 m	40247	87
IPV1	Record or Recall	76.1	12-23 m	40247	87
MCV1	Recall	11.8	12-23 m	40247	87
MCV1	Record	84.1	12-23 m	40247	87
MCV1	Record or Recall	95.9	12-23 m	40247	87
MCV1	Record2	5.2	12-23 m	40247	87
MCV2	Recall	8	24-35 m	40492	-
MCV2	Record	76.7	24-35 m	40492	-
MCV2	Record or Recall	92.6	24-35 m	40492	-
MCV2	Record2	7.9	24-35 m	40492	-
PCV1	Recall	12.1	12-23 m	40247	87
PCV1	Record	87.6	12-23 m	40247	87
PCV1	Record or Recall	99.7	12-23 m	40247	87
PCV1	Record2	5.4	12-23 m	40247	87
PCVC	Recall	12	12-23 m	40247	87
PCVC	Record	86.2	12-23 m	40247	87
PCVC	Record or Recall	98.2	12-23 m	40247	87
PCVC	Record2	5.3	12-23 m	40247	87
RCV1	Recall	11.8	12-23 m	40247	87
RCV1	Record	84.1	12-23 m	40247	87
RCV1	Record or Recall	95.9	12-23 m	40247	87
RCV1	Record2	5.2	12-23 m	40247	87

2017 Bangladesh EPI Coverage Evaluation Survey 2019

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	12.7	24-35 m	40492	-
BCG	Record	87.1	24-35 m	40492	-
BCG	Record or Recall	99.8	24-35 m	40492	-
DTP1	Recall	12.7	24-35 m	40492	-
DTP1	Record	87.1	24-35 m	40492	-
DTP1	Record or Recall	99.8	24-35 m	40492	-
DTP3	Recall	12.2	24-35 m	40492	-

Bangladesh - Survey Details

DTP3	Record	86.8	24-35 m	40492	-
DTP3	Record or Recall	99	24-35 m	40492	-
HEPB1	Recall	12.7	24-35 m	40492	-
HEPB1	Record	87.1	24-35 m	40492	-
HEPB1	Record or Recall	99.8	24-35 m	40492	-
HEPB3	Recall	12.2	24-35 m	40492	-
HEPB3	Record	86.8	24-35 m	40492	-
HEPB3	Record or Recall	99	24-35 m	40492	-
HIB1	Recall	12.7	24-35 m	40492	-
HIB1	Record	87.1	24-35 m	40492	-
HIB1	Record or Recall	99.8	24-35 m	40492	-
HIB3	Recall	12.2	24-35 m	40492	-
HIB3	Record	86.8	24-35 m	40492	-
HIB3	Record or Recall	99	24-35 m	40492	-
MCV1	Recall	11.1	24-35 m	40492	-
MCV1	Record	86	24-35 m	40492	-
MCV1	Record or Recall	97.1	24-35 m	40492	-
MCV1	Record2	8	24-35 m	40492	-
PCV1	Recall	12.7	24-35 m	40492	-
PCV1	Record	87.1	24-35 m	40492	-
PCV1	Record or Recall	99.8	24-35 m	40492	-
PCV1	Record2	8.1	24-35 m	40492	-
PCVC	Recall	12.3	24-35 m	40492	-
PCVC	Record	86.3	24-35 m	40492	-
PCVC	Record or Recall	98.6	24-35 m	40492	-
PCVC	Record2	8	24-35 m	40492	-
RCV1	Recall	11.1	24-35 m	40492	-
RCV1	Record	86	24-35 m	40492	-
RCV1	Record or Recall	97.1	24-35 m	40492	-
RCV1	Record2	8	24-35 m	40492	-

2016 Bangladesh Demographic and Health Survey 2017-2018

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	24.3	12-23 m	433	74
BCG	Record	74	12-23 m	1245	74
BCG	Record or Recall	98.3	12-23 m	1679	74
BCG	Record or Recall<12m	97.9	12-23 m	1679	74
DTP1	Recall	24.3	12-23 m	433	74

DTP1	Record	74.2	12-23 m	1245	74
DTP1	Record or Recall	98.5	12-23 m	1679	74
DTP1	Record or Recall<12m	98.4	12-23 m	1679	74
DTP3	Recall	22.6	12-23 m	433	74
DTP3	Record	73.3	12-23 m	1245	74
DTP3	Record or Recall	95.9	12-23 m	1679	74
DTP3	Record or Recall<12m	95.6	12-23 m	1679	74
HEPB1	Recall	24.3	12-23 m	433	74
HEPB1	Record	74.2	12-23 m	1245	74
HEPB1	Record or Recall	98.5	12-23 m	1679	74
HEPB1	Record or Recall<12m	98.4	12-23 m	1679	74
HEPB3	Recall	22.6	12-23 m	433	74
HEPB3	Record	73.3	12-23 m	1245	74
HEPB3	Record or Recall	95.9	12-23 m	1679	74
HEPB3	Record or Recall<12m	95.6	12-23 m	1679	74
HIB1	Recall	24.3	12-23 m	433	74
HIB1	Record	74.2	12-23 m	1245	74
HIB1	Record or Recall	98.5	12-23 m	1679	74
HIB1	Record or Recall<12m	98.4	12-23 m	1679	74
HIB3	Recall	22.6	12-23 m	433	74
HIB3	Record	73.3	12-23 m	1245	74
HIB3	Record or Recall	95.9	12-23 m	1679	74
HIB3	Record or Recall<12m	95.6	12-23 m	1679	74
IPV1	Recall	16.1	12-23 m	433	74
IPV1	Record	20.5	12-23 m	1245	74
IPV1	Record or Recall	36.6	12-23 m	1679	74
IPV1	Record or Recall<12m	32.1	12-23 m	1679	74
MCV1	Recall	21.7	12-23 m	433	74
MCV1	Record	69.3	12-23 m	1245	74
MCV1	Record or Recall	91	12-23 m	1679	74
MCV1	Record or Recall<12m	87.9	12-23 m	1679	74
MCV2	Recall	25.2	24-35 m	555	-
MCV2	Record	58	24-35 m	1130	-
MCV2	Record or Recall	83.1	24-35 m	1685	-
MCV2	Record or Recall<12m	81.8	24-35 m	1685	-
PCV1	Recall	23.7	12-23 m	433	74
PCV1	Record	73.8	12-23 m	1245	74
PCV1	Record or Recall	97.5	12-23 m	1679	74
PCV1	Record or Recall<12m	97.4	12-23 m	1679	74
PCVC	Recall	21.1	12-23 m	433	74

Bangladesh - Survey Details

PCVC	Record	70.9	12-23 m	1245	74
PCVC	Record or Recall	92	12-23 m	1679	74
PCVC	Record or Recall<12m	91.5	12-23 m	1679	74
RCV1	Recall	21.7	12-23 m	433	74
RCV1	Record	69.3	12-23 m	1245	74
RCV1	Record or Recall	91	12-23 m	1679	74
RCV1	Record or Recall<12m	87.9	12-23 m	1679	74

2015 Bangladesh Demographic and Health Survey 2017-2018

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	31.7	24-35 m	555	-
BCG	Record	67.1	24-35 m	1130	-
BCG	Record or Recall	98.7	24-35 m	1685	-
BCG	Record or Recall<12m	98.6	24-35 m	1685	-
DTP1	Recall	31.4	24-35 m	555	-
DTP1	Record	67	24-35 m	1130	-
DTP1	Record or Recall	98.3	24-35 m	1685	-
DTP1	Record or Recall<12m	98.2	24-35 m	1685	-
DTP3	Recall	30.2	24-35 m	555	-
DTP3	Record	65.9	24-35 m	1130	-
DTP3	Record or Recall	96.1	24-35 m	1685	-
DTP3	Record or Recall<12m	94.1	24-35 m	1685	-
HEPB1	Recall	31.4	24-35 m	555	-
HEPB1	Record	67	24-35 m	1130	-
HEPB1	Record or Recall	98.3	24-35 m	1685	-
HEPB1	Record or Recall<12m	98.2	24-35 m	1685	-
HEPB3	Recall	30.2	24-35 m	555	-
HEPB3	Record	65.9	24-35 m	1130	-
HEPB3	Record or Recall	96.1	24-35 m	1685	-
HEPB3	Record or Recall<12m	94.1	24-35 m	1685	-
HIB1	Recall	31.4	24-35 m	555	-
HIB1	Record	67	24-35 m	1130	-
HIB1	Record or Recall	98.3	24-35 m	1685	-
HIB1	Record or Recall<12m	98.2	24-35 m	1685	-
HIB3	Recall	30.2	24-35 m	555	-
HIB3	Record	65.9	24-35 m	1130	-
HIB3	Record or Recall	96.1	24-35 m	1685	-
HIB3	Record or Recall<12m	94.1	24-35 m	1685	-

IPV1	Recall	21.3	24-35 m	555	-
IPV1	Record	44	24-35 m	1130	-
IPV1	Record or Recall	65.3	24-35 m	1685	-
IPV1	Record or Recall<12m	63.4	24-35 m	1685	-
MCV1	Recall	28.8	24-35 m	555	-
MCV1	Record	64	24-35 m	1130	-
MCV1	Record or Recall	92.7	24-35 m	1685	-
MCV1	Record or Recall<12m	87.9	24-35 m	1685	-
PCV1	Recall	30.5	24-35 m	555	-
PCV1	Record	65.6	24-35 m	1130	-
PCV1	Record or Recall	96.2	24-35 m	1685	-
PCV1	Record or Recall<12m	96	24-35 m	1685	-
PCVC	Recall	29	24-35 m	555	-
PCVC	Record	63.5	24-35 m	1130	-
PCVC	Record or Recall	92.4	24-35 m	1685	-
PCVC	Record or Recall<12m	90.8	24-35 m	1685	-
RCV1	Recall	28.8	24-35 m	555	-
RCV1	Record	64	24-35 m	1130	-
RCV1	Record or Recall	92.7	24-35 m	1685	-
RCV1	Record or Recall<12m	87.9	24-35 m	1685	-

2015 Bangladesh EPI Coverage Evaluation Survey 2016

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	11.4	12-23 m	35112	83
BCG	Record	88.1	12-23 m	35112	83
BCG	Record or Recall	99.5	12-23 m	35112	83
BCG	Record or Recall<12m	99.5	12-23 m	35112	83
DTP1	Recall	11.3	12-23 m	35112	83
DTP1	Record	88	12-23 m	35112	83
DTP1	Record or Recall	99.3	12-23 m	35112	83
DTP1	Record or Recall<12m	99.2	12-23 m	35112	83
DTP3	Recall	11.2	12-23 m	35112	83
DTP3	Record	86.6	12-23 m	35112	83
DTP3	Record or Recall	97.9	12-23 m	35112	83
DTP3	Record or Recall<12m	97.5	12-23 m	35112	83
HEPB1	Recall	11.3	12-23 m	35112	83
HEPB1	Record	88	12-23 m	35112	83
HEPB1	Record or Recall	99.3	12-23 m	35112	83

Bangladesh - Survey Details

HEPB1	Record or Recall<12m	99.2	12-23 m	35112	83
HEPB3	Recall	11.2	12-23 m	35112	83
HEPB3	Record	86.6	12-23 m	35112	83
HEPB3	Record or Recall	97.9	12-23 m	35112	83
HEPB3	Record or Recall<12m	97.5	12-23 m	35112	83
HIB1	Recall	11.3	12-23 m	35112	83
HIB1	Record	88	12-23 m	35112	83
HIB1	Record or Recall	99.3	12-23 m	35112	83
HIB1	Record or Recall<12m	99.2	12-23 m	35112	83
HIB3	Recall	11.2	12-23 m	35112	83
HIB3	Record	86.6	12-23 m	35112	83
HIB3	Record or Recall	97.9	12-23 m	35112	83
HIB3	Record or Recall<12m	97.5	12-23 m	35112	83
MCV1	Recall	11.3	12-23 m	35112	83
MCV1	Record	84	12-23 m	35112	83
MCV1	Record or Recall	95.3	12-23 m	35112	83
MCV1	Record or Recall<12m	90.5	12-23 m	35112	83
MCV2	Record or Recall	86.4	18-29 m	35112	-
RCV1	Recall	11.3	12-23 m	35112	83
RCV1	Record	84	12-23 m	35112	83
RCV1	Record or Recall	95.3	12-23 m	35112	83
RCV1	Record or Recall<12m	90.5	12-23 m	35112	83

HEPB1	Record or Recall	99.3	12-23 m	16170	83
HEPB1	Record or Recall<12m	99.1	12-23 m	16170	83
HEPB1	Record<12m	81.4	12-23 m	16170	83
HEPB3	Record	79.8	12-23 m	16170	83
HEPB3	Record or Recall	97.3	12-23 m	16170	83
HEPB3	Record or Recall<12m	96.7	12-23 m	16170	83
HEPB3	Record<12m	79.3	12-23 m	16170	83
HIB1	Record	81.5	12-23 m	16170	83
HIB1	Record or Recall	99.3	12-23 m	16170	83
HIB1	Record or Recall<12m	99.1	12-23 m	16170	83
HIB1	Record<12m	81.4	12-23 m	16170	83
HIB3	Record	79.8	12-23 m	16170	83
HIB3	Record or Recall	97.3	12-23 m	16170	83
HIB3	Record or Recall<12m	96.7	12-23 m	16170	83
HIB3	Record<12m	79.3	12-23 m	16170	83
MCV1	Record	76.7	12-23 m	16170	83
MCV1	Record or Recall	94.4	12-23 m	16170	83
MCV1	Record or Recall<12m	90.1	12-23 m	16170	83
MCV1	Record<12m	73.2	12-23 m	16170	83
RCV1	Record	76.7	12-23 m	16170	83
RCV1	Record or Recall	94.4	12-23 m	16170	83
RCV1	Record or Recall<12m	90.1	12-23 m	16170	83
RCV1	Record<12m	73.2	12-23 m	16170	83

2014 Bangladesh EPI Coverage Evaluation Survey 2015

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record	81.5	12-23 m	16170	83
BCG	Record or Recall	99.4	12-23 m	16170	83
BCG	Record or Recall<12m	99.3	12-23 m	16170	83
BCG	Record<12m	81.5	12-23 m	16170	83
DTP1	Record	81.5	12-23 m	16170	83
DTP1	Record or Recall	99.3	12-23 m	16170	83
DTP1	Record or Recall<12m	99.1	12-23 m	16170	83
DTP1	Record<12m	81.4	12-23 m	16170	83
DTP3	Record	79.8	12-23 m	16170	83
DTP3	Record or Recall	97.3	12-23 m	16170	83
DTP3	Record or Recall<12m	96.7	12-23 m	16170	83
DTP3	Record<12m	79.3	12-23 m	16170	83
HEPB1	Record	81.5	12-23 m	16170	83

2012 Bangladesh Demographic and Health Survey, 2014

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	24.1	12-23 m	426	74
BCG	Record	73.8	12-23 m	1207	74
BCG	Record or Recall	97.9	12-23 m	1633	74
BCG	Record or Recall<12m	97.8	12-23 m	1633	74
DTP1	Recall	23.2	12-23 m	426	74
DTP1	Record	73.8	12-23 m	1207	74
DTP1	Record or Recall	97	12-23 m	1633	74
DTP1	Record or Recall<12m	97	12-23 m	1633	74
DTP3	Recall	20.5	12-23 m	426	74
DTP3	Record	70.8	12-23 m	1207	74
DTP3	Record or Recall	91.3	12-23 m	1633	74
DTP3	Record or Recall<12m	90.9	12-23 m	1633	74

Bangladesh - Survey Details

HEPB1	Recall	23.2	12-23 m	426	74
HEPB1	Record	73.8	12-23 m	1207	74
HEPB1	Record or Recall	97	12-23 m	1633	74
HEPB1	Record or Recall<12m	97	12-23 m	1633	74
HEPB3	Recall	20.5	12-23 m	426	74
HEPB3	Record	70.8	12-23 m	1207	74
HEPB3	Record or Recall	91.3	12-23 m	1633	74
HEPB3	Record or Recall<12m	90.9	12-23 m	1633	74
HIB1	Recall	23.2	12-23 m	426	74
HIB1	Record	73.8	12-23 m	1207	74
HIB1	Record or Recall	97	12-23 m	1633	74
HIB1	Record or Recall<12m	97	12-23 m	1633	74
HIB3	Recall	20.5	12-23 m	426	74
HIB3	Record	70.8	12-23 m	1207	74
HIB3	Record or Recall	91.3	12-23 m	1633	74
HIB3	Record or Recall<12m	90.9	12-23 m	1633	74
MCV1	Recall	20.3	12-23 m	426	74
MCV1	Record	65.8	12-23 m	1207	74
MCV1	Record or Recall	86.1	12-23 m	1633	74
MCV1	Record or Recall<12m	79.9	12-23 m	1633	74

2012 Bangladesh EPI Coverage Evaluation Survey 2014

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record	82	12-23 m	16170	83
BCG	Record or Recall	99.2	12-23 m	16170	83
DTP1	Record	81.8	12-23 m	16170	83
DTP1	Record or Recall	99	12-23 m	16170	83
DTP1	Record<12m	81.7	12-23 m	16170	83
DTP3	Record	79.7	12-23 m	16170	83
DTP3	Record or Recall	97.1	12-23 m	16170	83
DTP3	Record or Recall<12m	96.8	12-23 m	16170	83
DTP3	Record<12m	79.4	12-23 m	16170	83
HEPB1	Record	81.8	12-23 m	16170	83
HEPB1	Record or Recall	99	12-23 m	16170	83
HEPB1	Record or Recall<12m	99	12-23 m	16170	83
HEPB1	Record<12m	81.7	12-23 m	16170	83
HEPB3	Record	79.7	12-23 m	16170	83
HEPB3	Record or Recall	97.1	12-23 m	16170	83

HEPB3	Record or Recall<12m	96.8	12-23 m	16170	83
HEPB3	Record<12m	79.4	12-23 m	16170	83
HIB1	Record	81.8	12-23 m	16170	83
HIB1	Record or Recall	99	12-23 m	16170	83
HIB1	Record or Recall<12m	99	12-23 m	16170	83
HIB1	Record<12m	81.7	12-23 m	16170	83
HIB3	Record	79.7	12-23 m	16170	83
HIB3	Record or Recall	97.1	12-23 m	16170	83
HIB3	Record or Recall<12m	96.8	12-23 m	16170	83
HIB3	Record<12m	79.4	12-23 m	16170	83
MCV1	Record	74.6	12-23 m	16170	83
MCV1	Record or Recall	93.2	12-23 m	16170	83
MCV1	Record or Recall<12m	89.7	12-23 m	16170	83
MCV1	Record<12m	71.8	12-23 m	16170	83

2012 Bangladesh Utilization of Essential Service Delivery Survey 2013

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	24.6	12-23 m	233	74
BCG	Record	73.7	12-23 m	654	74
BCG	Record or Recall	98.2	12-23 m	887	74
BCG	Record or Recall<12m	97.7	12-23 m	887	74
DTP1	Recall	24.5	12-23 m	233	74
DTP1	Record	71	12-23 m	654	74
DTP1	Record or Recall	95.5	12-23 m	887	74
DTP1	Record or Recall<12m	94.8	12-23 m	887	74
DTP3	Recall	22.9	12-23 m	233	74
DTP3	Record	68.7	12-23 m	654	74
DTP3	Record or Recall	91.6	12-23 m	887	74
DTP3	Record or Recall<12m	90.6	12-23 m	887	74
HEPB1	Recall	24.5	12-23 m	233	74
HEPB1	Record	71	12-23 m	654	74
HEPB1	Record or Recall	95.5	12-23 m	887	74
HEPB1	Record or Recall<12m	94.8	12-23 m	887	74
HEPB3	Recall	22.9	12-23 m	233	74
HEPB3	Record	68.7	12-23 m	654	74
HEPB3	Record or Recall	91.6	12-23 m	887	74
HEPB3	Record or Recall<12m	90.6	12-23 m	887	74
HIB1	Recall	24.5	12-23 m	233	74

Bangladesh - Survey Details

HIB1	Record	71	12-23 m	654	74
HIB1	Record or Recall	95.5	12-23 m	887	74
HIB1	Record or Recall<12m	94.8	12-23 m	887	74
HIB3	Recall	22.9	12-23 m	233	74
HIB3	Record	68.7	12-23 m	654	74
HIB3	Record or Recall	91.6	12-23 m	887	74
HIB3	Record or Recall<12m	90.6	12-23 m	887	74
MCV1	Recall	21	12-23 m	233	74
MCV1	Record	64.4	12-23 m	654	74
MCV1	Record or Recall	85.4	12-23 m	887	74
MCV1	Record or Recall<12m	81.9	12-23 m	887	74

HIB3	Recall	20.6	12-23 m	15960	81
HIB3	Record	76.4	12-23 m	15960	81
HIB3	Record or Recall	97	12-23 m	15960	81
HIB3	Record or Recall<12m	NA	12-23 m	15960	81
MCV1	Recall	21.3	12-23 m	15960	81
MCV1	Record	71.5	12-23 m	15960	81
MCV1	Record or Recall	92.8	12-23 m	15960	81
MCV1	Record or Recall<12m	NA	12-23 m	15960	81

2010 Bangladesh Demographic and Health Survey 2011

2011 EPI Coverage Evaluation Survey, 2013

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	20.7	12-23 m	15960	81
BCG	Record	78.6	12-23 m	15960	81
BCG	Record or Recall	99.3	12-23 m	15960	81
BCG	Record or Recall<12m	NA	12-23 m	15960	81
DTP1	Recall	20.8	12-23 m	15960	81
DTP1	Record	78.3	12-23 m	15960	81
DTP1	Record or Recall	99.1	12-23 m	15960	81
DTP1	Record or Recall<12m	NA	12-23 m	15960	81
DTP3	Recall	20.6	12-23 m	15960	81
DTP3	Record	76.4	12-23 m	15960	81
DTP3	Record or Recall	97	12-23 m	15960	81
DTP3	Record or Recall<12m	NA	12-23 m	15960	81
HEPB1	Recall	20.8	12-23 m	15960	81
HEPB1	Record	78.3	12-23 m	15960	81
HEPB1	Record or Recall	99.1	12-23 m	15960	81
HEPB1	Record or Recall<12m	NA	12-23 m	15960	81
HEPB3	Recall	20.6	12-23 m	15960	81
HEPB3	Record	76.4	12-23 m	15960	81
HEPB3	Record or Recall	97	12-23 m	15960	81
HEPB3	Record or Recall<12m	NA	12-23 m	15960	81
HIB1	Recall	20.8	12-23 m	15960	81
HIB1	Record	78.3	12-23 m	15960	81
HIB1	Record or Recall	99.1	12-23 m	15960	81
HIB1	Record or Recall<12m	NA	12-23 m	15960	81

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	31.1	12-23 m	515	67
BCG	Record	66.7	12-23 m	1032	67
BCG	Record or Recall	97.8	12-23 m	1547	67
BCG	Record or Recall<12m	97.8	12-23 m	1547	67
DTP1	Recall	31.1	12-23 m	515	67
DTP1	Record	66.7	12-23 m	1032	67
DTP1	Record or Recall	97.8	12-23 m	1547	67
DTP1	Record or Recall<12m	97.8	12-23 m	1547	67
DTP3	Recall	29.2	12-23 m	515	67
DTP3	Record	64.2	12-23 m	1032	67
DTP3	Record or Recall	93.4	12-23 m	1547	67
DTP3	Record or Recall<12m	93.2	12-23 m	1547	67
HEPB1	Recall	31.1	12-23 m	515	67
HEPB1	Record	66.7	12-23 m	1032	67
HEPB1	Record or Recall	97.8	12-23 m	1547	67
HEPB1	Record or Recall<12m	97.8	12-23 m	1547	67
HEPB3	Recall	29.2	12-23 m	515	67
HEPB3	Record	64.2	12-23 m	1032	67
HEPB3	Record or Recall	93.4	12-23 m	1547	67
HEPB3	Record or Recall<12m	93.2	12-23 m	1547	67
HIB1	Recall	31.1	12-23 m	515	67
HIB1	Record	66.7	12-23 m	1032	67
HIB1	Record or Recall	97.8	12-23 m	1547	67
HIB1	Record or Recall<12m	97.8	12-23 m	1547	67
HIB3	Recall	29.2	12-23 m	515	67
HIB3	Record	64.2	12-23 m	1032	67
HIB3	Record or Recall	93.4	12-23 m	1547	67

Bangladesh - Survey Details

HIB3	Record or Recall<12m	93.2	12-23 m	1547	67
MCV1	Recall	27.9	12-23 m	515	67
MCV1	Record	59.6	12-23 m	1032	67
MCV1	Record or Recall	87.5	12-23 m	1547	67
MCV1	Record or Recall<12m	84	12-23 m	1547	67

2009 Bangladesh EPI Coverage Evaluation Survey 2010

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record or Recall	98.9	12-23 m	14700	72
DTP1	Record or Recall	98.7	12-23 m	14700	72
DTP3	Record or Recall	96.9	12-23 m	14700	72
HEPB1	Record or Recall	98.7	12-23 m	14700	72
HEPB3	Record or Recall	96.9	12-23 m	14700	72
MCV1	Record or Recall	93.2	12-23 m	14700	72

2008 Bangladesh EPI Coverage Evaluation Survey 2009

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	29.2	12-23 m	15120	73
BCG	Record	69.8	12-23 m	15120	73
BCG	Record or Recall	99	12-23 m	15120	73
DTP1	Recall	29.2	12-23 m	15120	73
DTP1	Record	69.7	12-23 m	15120	73
DTP1	Record or Recall	98.9	12-23 m	15120	73
DTP3	Recall	29.4	12-23 m	15120	73
DTP3	Record	67.5	12-23 m	15120	73
DTP3	Record or Recall	96.9	12-23 m	15120	73
HEPB1	Recall	29.2	12-23 m	15120	73
HEPB1	Record	69.7	12-23 m	15120	73
HEPB1	Record or Recall	98.9	12-23 m	15120	73
HEPB3	Recall	29.4	12-23 m	15120	73
HEPB3	Record	67.5	12-23 m	15120	73
HEPB3	Record or Recall	96.9	12-23 m	15120	73
MCV1	Recall	30.5	12-23 m	15120	73
MCV1	Record	61.7	12-23 m	15120	73
MCV1	Record or Recall	92.2	12-23 m	15120	73

2007 Bangladesh EPI Coverage Evaluation Survey 2007

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	33	12-23 m	5670	68
BCG	Record	65.4	12-23 m	5670	68
BCG	Record or Recall	98.4	12-23 m	5670	68
DTP1	Recall	32.7	12-23 m	5670	68
DTP1	Record	65.6	12-23 m	5670	68
DTP1	Record or Recall	98.3	12-23 m	5670	68
DTP3	Recall	32.2	12-23 m	5670	68
DTP3	Record	63.1	12-23 m	5670	68
DTP3	Record or Recall	95.3	12-23 m	5670	68
HEPB1	Recall	32.9	12-23 m	5670	68
HEPB1	Record	65.4	12-23 m	5670	68
HEPB1	Record or Recall	98.3	12-23 m	5670	68
HEPB3	Recall	32.4	12-23 m	5670	68
HEPB3	Record	62.8	12-23 m	5670	68
HEPB3	Record or Recall	95.2	12-23 m	5670	68
MCV1	Recall	32.5	12-23 m	5670	68
MCV1	Record	56.7	12-23 m	5670	68
MCV1	Record or Recall	89.2	12-23 m	5670	68

2006 Bangladesh Demographic and Health Survey 2007

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	38.7	12-23 m	1146	58
BCG	Record	58.1	12-23 m	1146	58
BCG	Record or Recall	96.8	12-23 m	1146	58
BCG	Record or Recall<12m	96.8	12-23 m	1146	58
DTP1	Recall	38.6	12-23 m	1146	58
DTP1	Record	58.2	12-23 m	1146	58
DTP1	Record or Recall	96.8	12-23 m	1146	58
DTP1	Record or Recall<12m	96.8	12-23 m	1146	58
DTP3	Recall	35	12-23 m	1146	58
DTP3	Record	56.1	12-23 m	1146	58
DTP3	Record or Recall	91.1	12-23 m	1146	58
DTP3	Record or Recall<12m	90	12-23 m	1146	58
HEPB1	Recall	32.9	12-23 m	1146	58

Bangladesh - Survey Details

HEPB1	Record	56	12-23 m	1146	58
HEPB1	Record or Recall	88.9	12-23 m	1146	58
HEPB1	Record or Recall<12m	88.9	12-23 m	1146	58
HEPB3	Recall	28.9	12-23 m	1146	58
HEPB3	Record	53.9	12-23 m	1146	58
HEPB3	Record or Recall	82.7	12-23 m	1146	58
HEPB3	Record or Recall<12m	81.4	12-23 m	1146	58
MCV1	Recall	31.1	12-23 m	1146	58
MCV1	Record	52	12-23 m	1146	58
MCV1	Record or Recall	83.1	12-23 m	1146	58
MCV1	Record or Recall<12m	77.2	12-23 m	1146	58

2005 Bangladesh Multiple Indicator Cluster Survey 2006

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	31.7	12-23 m	6032	66
BCG	Record	65.3	12-23 m	6032	66
BCG	Record or Recall	97	12-23 m	6032	66
BCG	Record or Recall<12m	96.7	12-23 m	6032	66
DTP1	Recall	31.3	12-23 m	6032	66
DTP1	Record	65.2	12-23 m	6032	66
DTP1	Record or Recall	96.6	12-23 m	6032	66
DTP1	Record or Recall<12m	96.3	12-23 m	6032	66
DTP3	Recall	28.5	12-23 m	6032	66
DTP3	Record	61.7	12-23 m	6032	66
DTP3	Record or Recall	90.1	12-23 m	6032	66
DTP3	Record or Recall<12m	89.7	12-23 m	6032	66
HEPB1	Recall	2.8	12-23 m	6032	66
HEPB1	Record	46	12-23 m	6032	66
HEPB1	Record or Recall	48.7	12-23 m	6032	66
HEPB1	Record or Recall<12m	48.5	12-23 m	6032	66
HEPB3	Recall	1.9	12-23 m	6032	66
HEPB3	Record	41.7	12-23 m	6032	66
HEPB3	Record or Recall	43.6	12-23 m	6032	66
HEPB3	Record or Recall<12m	43	12-23 m	6032	66
MCV1	Recall	33.3	12-23 m	6032	66
MCV1	Record	54.2	12-23 m	6032	66
MCV1	Record or Recall	87.5	12-23 m	6032	66
MCV1	Record or Recall<12m	85.3	12-23 m	6032	66

2004 Bangladesh EPI Coverage Evaluation Survey 2005

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record	100	12-23 m	15120	65
BCG	Record or Recall	96	12-23 m	15120	65
DTP1	Record	88	12-23 m	15120	65
DTP1	Record or Recall	96	12-23 m	15120	65
DTP3	Record	100	12-23 m	15120	65
DTP3	Record or Recall	88	12-23 m	15120	65
MCV1	Record	88	12-23 m	15120	65
MCV1	Record or Recall	81	12-23 m	15120	65

2003 Bangladesh Demographic and Health Survey 2004

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	44	12-23 m	1265	49
BCG	Record	49.4	12-23 m	1265	49
BCG	Record or Recall	93.4	12-23 m	1265	49
BCG	Record or Recall<12m	93.3	12-23 m	1265	49
DTP1	Recall	43.7	12-23 m	1265	49
DTP1	Record	49.3	12-23 m	1265	49
DTP1	Record or Recall	93.1	12-23 m	1265	49
DTP1	Record or Recall<12m	92.9	12-23 m	1265	49
DTP3	Recall	35.2	12-23 m	1265	49
DTP3	Record	45.8	12-23 m	1265	49
DTP3	Record or Recall	81	12-23 m	1265	49
DTP3	Record or Recall<12m	80.3	12-23 m	1265	49
MCV1	Recall	34	12-23 m	1265	49
MCV1	Record	41.7	12-23 m	1265	49
MCV1	Record or Recall	75.7	12-23 m	1265	49
MCV1	Record or Recall<12m	70.3	12-23 m	1265	49

2002 Bangladesh EPI Coverage Evaluation Survey 2003

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record or Recall	95	12-23 m	3150	63

DTP1	Record or Recall	95	12-23 m	3150	63
DTP3	Record or Recall	83	12-23 m	3150	63
MCV1	Record or Recall	75	12-23 m	3150	63

2001 Bangladesh EPI Coverage Evaluation Survey 2002

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record or Recall	95	12-23 m	15750	55
DTP1	Record or Recall	94	12-23 m	15750	55
DTP3	Record or Recall	85	12-23 m	15750	55
MCV1	Record or Recall	77	12-23 m	15750	55

2000 National Coverage Evaluation Survey Bangladesh 2001

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record or Recall	94	12-23 m	-	52
DTP1	Record or Recall	93	12-23 m	-	52
DTP3	Record or Recall	83	12-23 m	-	52
MCV1	Record or Recall	76	12-23 m	-	52

1999 Bangladesh, Multiple Indicator Cluster Survey 2000

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record or Recall	92.2	12-23 m	-	-
DTP1	Record or Recall	91.4	12-23 m	-	-
DTP3	Record or Recall	74.4	12-23 m	-	-
MCV1	Record or Recall	76.1	12-23 m	-	-

1999 National Coverage Evaluation Survey Bangladesh 2000

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record or Recall	96	12-23 m	-	52
DTP1	Record or Recall	95	12-23 m	-	52
DTP3	Record or Recall	81	12-23 m	-	52
MCV1	Record or Recall	71	12-23 m	-	52

1998 Bangladesh Demographic and Health Survey 1999-2000, 2001

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Recall	47.6	12-23 m	1316	44
BCG	Record	43.4	12-23 m	1316	44
BCG	Record or Recall	91	12-23 m	1316	44
BCG	Record or Recall<12m	90	12-23 m	1316	44
DTP1	Recall	45.4	12-23 m	1316	44
DTP1	Record	43.5	12-23 m	1316	44
DTP1	Record or Recall	88.9	12-23 m	1316	44
DTP1	Record or Recall<12m	88.4	12-23 m	1316	44
DTP3	Recall	34	12-23 m	1316	44
DTP3	Record	38.1	12-23 m	1316	44
DTP3	Record or Recall	72.1	12-23 m	1316	44
DTP3	Record or Recall<12m	70.2	12-23 m	1316	44
MCV1	Recall	36.5	12-23 m	1316	44
MCV1	Record	34.4	12-23 m	1316	44
MCV1	Record or Recall	70.8	12-23 m	1316	44
MCV1	Record or Recall<12m	62.1	12-23 m	1316	44

1997 National Coverage Evaluation Survey Bangladesh 1998

Vaccine	Confirmation method	Coverage	Age cohort	Sample	Evidence seen
BCG	Record	100	12-23 m	-	54
BCG	Record or Recall	92	12-23 m	-	54
BCG	Record or Recall<12m	91	12-23 m	-	54
BCG	Record<12m	99	12-23 m	-	54
DTP3	Record	91	12-23 m	-	54
DTP3	Record or Recall	78	12-23 m	-	54
DTP3	Record or Recall<12m	68	12-23 m	-	54
DTP3	Record<12m	77	12-23 m	-	54
MCV1	Record	84	12-23 m	-	54
MCV1	Record or Recall	72	12-23 m	-	54
MCV1	Record or Recall<12m	62	12-23 m	-	54
MCV1	Record<12m	74	12-23 m	-	54

Further information and estimates for previous years are available at:

<https://data.unicef.org/topic/child-health/immunization/>

<https://immunizationdata.who.int/listing.html>